Company News-宜明昂科英文

2026-01-21

ImmuneOnco Presents at J.P. Morgan Healthcare Conference: Biotech Showcase™ Presentation Highlights Progress of Core Programs Including IMM01

Recently, a three-person delegation from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) attended the 44th J.P. Morgan Healthcare Conference. Dr.

2026-01-19

ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension

Shanghai, China, January 19, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,

2026-01-14

Palverafusp α (IMM2510) Receives NMPA Approval for Phase II/III Clinical Trial in Endometrial Cancer

Shanghai, China, January 14, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the Investigational New Drug (IND) application for a Phase II

2026-01-12

ImmuneOnco Biopharmaceuticals' timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis

Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp

2026-01-09

ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™

Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t